Status:
COMPLETED
Special Investigation (All Cases) of LipaCreon in Patients With Pancreatic Exocrine Insufficiency Due to Cystic Fibrosis
Lead Sponsor:
Mylan Inc.
Conditions:
Cystic Fibrosis
Exocrine Pancreatic Insufficiency
Eligibility:
All Genders
1-99 years
Brief Summary
This study aims at collecting the information related to the safety and effectiveness in the pancreatic exocrine insufficiency patients due to cystic fibrosis receiving the treatment with LipaCreon in...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Patients who receive LipaCreon for the replacement of pancreatic digestive enzymes in pancreatic exocrine insufficiency due to cystic fibrosis
- Exclusion Criteria
- Patients with a history of hypersensitivity to the ingredient of LipaCreon.
- Patients with a history of hypersensitivity to porcine protein
Exclusion
Key Trial Info
Start Date :
August 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2018
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01427712
Start Date
August 1 2011
End Date
March 1 2018
Last Update
June 10 2022
Active Locations (21)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 73813
Aichi, Japan, 462-8508
2
Site reference ID/Investigator # 96698
Aichi, Japan, 466-8650
3
Research facility ID ORG-000141
Aichi, Japan, 467-8602
4
Site reference ID/Investigator no. ORG-000842
Aichi, Japan, 470-0224